Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte will present at the Jefferies Global Healthcare Conference on June 6, 2024, in New York, NY. The company's Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will lead the presentation at 1:00 p.m. ET. Humacyte specializes in developing bioengineered human tissues and aims to share significant updates and engage in one-on-one meetings. The event will be held at the Marriott Marquis, and a webcast will be available for a time on Humacyte's website.
Humacyte, Inc. (Nasdaq: HUMA) will be participating in upcoming investor conferences in May, with their top executives representing the company. The conferences include H.C. Wainwright BioConnect Investor Conference and Benchmark's 4th Annual Healthcare House Call Investor Conference. The participation aims to showcase their bioengineered human tissue technology on a commercial scale.
Humacyte, a biotechnology company, announced its first-quarter 2024 financial results, including the acceptance of its Biologics License Application (BLA) for HAV™ by the FDA and a PDUFA date set for August 10, 2024. The company raised $43 million from a public offering and highlighted milestones for the planned U.S. launch of its bioengineered human tissue. Recent accomplishments include FDA inspection completion, Budget Impact Model completion, and hiring a Vice President of Sales. The company presented advancements in the HAV for vascular trauma and dialysis access. Financially, they reported $115.5 million in cash, with no revenue but increased net cash provided from funding arrangements.
Humacyte, Inc. (Nasdaq: HUMA) will announce its first quarter financial results on May 10, 2024. The company focuses on developing bioengineered human tissue at scale. A conference call will follow to provide a corporate and financial update.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.